QTTB241115P45000
- 3.57
- 0.000.00%
Q32 Bio Newsroom
Raymond James Initiates Q32 Bio at Strong Buy With $90 Price Target
Oppenheimer Maintains Q32 Bio(QTTB.US) With Buy Rating, Raises Target Price to $80
Express News | Q32 Bio To Reveal Phase 1 Clinical Trial Results For Tissue-Targeted Complement Inhibitor ADX-097 At The American Society Of Nephrology Kidney Week 2024
Q32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes
Q32 Bio Initiated at Overweight by Wells Fargo
Q32 Bio Analyst Ratings
Wells Fargo Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $95
Q32 Bio to Participate in Upcoming September Investor Conferences
Piper Sandler Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $60
Piper Sandler Sticks to Their Buy Rating for Q32 Bio (QTTB)
Piper Sandler Maintains Q32 Bio(QTTB.US) With Buy Rating, Raises Target Price to $60
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Immunovant (IMVT) and Q32 Bio (QTTB)
Analysts Are Bullish on These Healthcare Stocks: Q32 Bio (QTTB), Wave Life Sciences (WVE)
Q32 Bio Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results.
Express News | Q32 Bio Inc : Piper Sandler Raises Target Price to $60 From $45
Express News | Q32 Bio's Cash, Cash Equivalents, And Short-term Investments Of $107.6M As Of June 30, 2024, Expected To Provide Financial Runway Through Four Phase 2 Clinical Milestones And Into Mid-2026
Express News | Q32 Bio Q2 2024 GAAP EPS $(1.42) Misses $(1.04) Estimate
Press Release: Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Q32 Bio | 10-Q: Quarterly report
Q32 Bio: Q2 Earnings Snapshot